FindMyKOL

Diana Barb, MD

Basic profile

University of Florida Health

ORCIDOn fileNPIOn fileSign in to see identifiers
✓ Itemized record
RegionGainesville, FL · SoutheastSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLFindMyKOL type: NationalLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

Diana Barb is an Endocrinology/Metabolic physician affiliated with University of Florida Health. OpenAlex indexes 93 publications with 6,858 citations (h-index 24).

Overview

Scholarship

indexed output and impact (OpenAlex)
93publications

Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.

6,858citations

Citations across these publications.

24h-index

H-index from these publications.

Clinical & industry

trials, payments and federal funding
3companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓

Industry payments

3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

  • Boehringer Ingelheim Pharmaceuticals, Inc.
    Program year20251 payment
    $87
  • Novo Nordisk Inc
    Program year20251 payment
    $58
  • Madrigal Pharmaceuticals
    Program year20251 payment
    $55
All 4 payment records: search, sort and filter.Explore →

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Hormonal (systemic)

    44.4%
    l-Thyroxine42%
    Levothyroxine Sodium70%Synthroid30%
    Part D≥47 patients
    Thyroid Hormone Synthesis Inhibitor2.4%
    Methimazole100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    37.5%
    Biguanide (metformin)12.4%
    Metformin Hcl65%Metformin Hcl Er35%
    Part D<11 patients
    SGLT2 inhibitor7.2%
    Jardiance100%
    Part D<11 patients

    + 3 more classes in this area

  • Sensory organs

    6.8%
    Corticosteroid6.8%
    Hydrocortisone100%
    Part D<11 patients
Where care is delivered (Part B)30.1% facility · 69.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”